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ABSTRACT
BACKGROUNDAND PURPOSE: Standard neuroimaging fails in defining the anatomy of the substantia nigra and has a marginal role in the
diagnosis of Parkinson disease. Recently 7T MR target imaging of the substantia nigra has been useful in diagnosing Parkinson disease. We
performed a comparative study to evaluate whether susceptibility-weighted angiography can diagnose Parkinson disease with a 3T
scanner.
MATERIALS ANDMETHODS: Fourteen patients with Parkinson disease and 13 healthy subjects underwent MR imaging examination at 3T
and 7T by using susceptibility-weighted angiography. Two expert blinded observers and 1 neuroradiology fellow evaluated the 3T and 7T
images of the sample to identify substantia nigra abnormalities indicative of Parkinson disease. Diagnostic accuracy and intra- and
interobserver agreement were calculated separately for 3T and 7T acquisitions.
RESULTS: Susceptibility-weighted angiography 7T MR imaging can diagnose Parkinson disease with a mean sensitivity of 93%, specificity
of 100%, and diagnostic accuracy of 96%. 3TMR imaging diagnosed Parkinson diseasewith amean sensitivity of 79%, specificity of 94%, and
diagnostic accuracy of 86%. Intraobserver and interobserver agreement was excellent at 7T. At 3T, intraobserver agreement was excellent
for experts, and interobserver agreement ranged between good and excellent. The less expert reader obtained a diagnostic accuracy of
89% at 3T.
CONCLUSIONS: Susceptibility-weighted angiography images obtained at 3T and 7T differentiate controls from patients with Parkinson
disease with a higher diagnostic accuracy at 7T. The capability of 3T in diagnosing Parkinson disease might encourage its use in clinical
practice. The use of the more accurate 7T should be supported by a dedicated cost-effectiveness study.
ABBREVIATIONS: HS healthy subjects; PD Parkinson disease; SN substantia nigra; SWAN susceptibility-weighted angiography; UHF ultra-high-field
Parkinson disease (PD) is a common neurodegenerative dis-ease whose pathologic substrate is nigrostriatal dopaminergic
degeneration due to the neuronal loss in the pars compacta of the
substantia nigra (SN).1
On the basis of the correlation between MR signal intensity at
conventional field strengths and Perls staining for iron distribu-
tion, the medial portion of the midbrain with lower MR signal is
attributed to the pars reticulata of the substantia nigra, and the
lateral region (with higherMR signal), to the substantia nigra pars
compacta.2 However, Perls staining and T2WI signal hypointen-
sity do not match precisely,3 and the hypointense area on T2WI
does not match the substantia nigra pars reticulata.4 Moreover,
conventional MR imaging techniques, including segmented in-
version recovery ratio imaging,5 fail to distinguish the inner struc-
ture of the substantia nigra.6 More advanced and recently pro-
posed SN-derived biomarkers such as relaxometry,7,8 DTI,9 and
neuromelanin imaging10 are currently not yet accepted in evalu-
ating patients with PD in clinical practice.11
Recently, by using high-resolution 3D susceptibility-weighted
angiography (SWAN),12 the ultra-high-field (UHF) anatomy of
the SN with its inner organization has been described13 as a
3-layer structure of different signal intensities along the posterior-
Received May 31, 2014; accepted after revision August 29.
From the IMAGO7 Foundation (M. Cosottini, M. Costagli), Pisa, Italy; Department
of Translational Research and New Technologies in Medicine and Surgery
(M. Cosottini, G.D.) and Neurology Unit (D.F., R.C., U.B.), Department of Clinical and
Experimental Medicine, University of Pisa, Pisa, Italy; Neuroradiology Unit (I.P., P.C.),
Department of Diagnostic and Interventional Radiology, Azienda Ospedaliero Uni-
versitaria Pisana, Pisa, Italy; and Stella Maris Scientific Institute (L.B., M.T.), Pisa, Italy.
The study is part of an experimental protocol named “Clinical Impact of Ultra-
High-Field MRI in Neurodegenerative Diseases Diagnosis,” RF-2009-1546281, ap-
proved and funded by Italian Ministry of Health and co-funded by the Health Ser-
vice of Tuscany.
Please address correspondence to Mirco Cosottini, MD, Via Paradisa 2, 56124
Cisanello Pisa, Italy; e-mail: mircocosottini@libero.it
Indicates open access to non-subscribers at www.ajnr.org
Indicates article with supplemental on-line photo.
http://dx.doi.org/10.3174/ajnr.A4158
AJNR Am J Neuroradiol 36:461–66 Mar 2015 www.ajnr.org 461
anterior axis of the midbrain, resembling the dorsal and ventral
components of the substantia nigra pars compacta and the sub-
stantia nigra pars reticulata, respectively. By using calbindin im-
munostaining, one can distinguish calbindin-positive (matrix)
and calbindin-negative structures (nigrosomes)14 within the sub-
stantia nigra. In a recent MR imaging study at 7T,15 nigrosome 1,
the largest and highly attenuated cluster of calbindin-negative neu-
rons within the substantia nigra pars compacta ventralis, corre-
sponded to the roundhyperintenseareaobserved in the intermediate
and lateral portion of the substantia nigra pars compacta.16
In patients with PD the 3-layer organization and the hyperin-
tense lateral spot within the SN (nigrosome 1) are lost, and this
radiologic sign distinguishes patients with PD from healthy sub-
jects (HS) on an individual basis with high accuracy.13
The diagnostic gain provided by 7T imaging is a prerequisite
for the clinical acceptance of UHF, but until now, 7TMR imaging
examinations have been confined to the research environment.
The neuroimaging-based diagnosis of PDmight constitute an im-
portant addition to the clinical diagnosis of extrapyramidal disor-
ders. Therefore, the diagnostic role of SWI performed with a clin-
ical MR imaging scanner at 3T has been tested recently,17,18 with
promising results. A direct comparison of 3T and 7T evaluation of
the SN is mentioned in a pilot experience including 2 patients
with PD.15
Here, we describe a comparative study with a case control
design that prospectively evaluates the diagnostic accuracy of
SWAN at 3T and 7T.
MATERIALS AND METHODS
Subjects
Fourteen patients with PD according to the clinical criteria for
probable PD of the UK Parkinson’s Disease Society Brain Bank19
were consecutively enrolled from a tertiary movement disorder
center.
Patients (6 women and 8 men; mean age, 57.4 years; range,
39–69 years) had a disease mean duration at the moment of en-
rollment of 58 months (range, 6–120 months); the range of
Hoehn and Yahr Scale20 was 1–2, and the motor part of the Uni-
fied Parkinson Disease Rating Scale21 was 18.3 (range, 9–37).
Thirteen right-handed HS (4 women and 9 men; mean age,
54.8 years; range, 41–66 years) were enrolled to test the diagnostic
accuracy of the SN MR imaging examination in discriminating
patients with PD from controls. All HS were volunteers and had
no personal or family history of psychiatric and neurologic disor-
ders; their general and neurologic examination findings were
unremarkable.
All patients and controls gave their informed consent to the
enrollment and diagnostic procedures on the basis of the adher-
ence to an experimental protocol called “Clinical Impact of Ultra-
High-Field MRI in Neurodegenerative Diseases Diagnosis,” RF-
2009-1546281, approved and funded by the Italian Ministry of
Health and co-funded by theHealth Service of Tuscany. The local
competent ethics committee approved the study.
MR Imaging Acquisition
MR imaging examinations were performed in patients and con-
trols by using a Discovery MR 950 7T imaging scanner (GE
Healthcare, Milwaukee, Wisconsin) equipped with a 2CH-TX/
32CH-RX head coil (NovaMedical, Wilmington, Massachusetts)
and a Discovery MR 750 3T scanner (GE Healthcare) equipped
with an 8-channel head coil. Patients and controls underwent
both 7T and 3T examination in a random order but within 1
month of recruitment.
The same technicians optimized the 3D multiecho gradient-
recalled sequence (SWAN) at 7T and 3T.
TheMR imaging parameters at 7Twere TE 5.57, 10.7, 15.84,
20.97, 26.1, 31.23, 36.36, 41.5 ms; TR 55.7 ms; flip angle 8°;
NEX 0.67; in-plane resolution 312m; thickness 1.2mm;
18 partitions; receiver bandwidth 67 KHz.
TheMR imaging parameters at 3Twere TE 13, 17.96, 22.93,
27.89, 32.86, 37.82, 42.78, 47.75, 52.71, 57.68, 62.64ms; TR 67.2
ms; flip angle 15°; NEX 0.68; in-plane resolution 394m;
thickness  1.2 mm; 18 partitions; receiver bandwidth  62.5
KHz.
The SWANacquisitions on bothMR imaging systems targeted
the midbrain and were oriented perpendicularly to the fourth
ventricle floor.
The final output image was reconstructed into a 512 512
18 matrix by averaging the images obtained for each single echo.
The SWAN acquisition time was 4 minutes 2 seconds at 7T and 4
minutes 20 seconds at 3T.
Image Analysis
According to themethodology of a previous study,13 the SN anat-
omy was evaluated along the rostrocaudal axis at the level of the
inferior third of the red nucleus (level I) and at the level of the
superior cerebellar peduncle decussation (level II), where the sig-
nal changes were more informative for diagnosing PD. Anatomy
was considered normal if the SN at level I was characterized by a
medial homogeneous hypointense region and by a lateral hyper-
intense spot between 2 hypointense layers and if a trilaminar or-
ganization characterized by a central hyperintense layer between 2
hypointense laminae was detectable at level II.
The criteria for abnormal SN anatomy were the loss of the
hyperintense lateral spot at level I or/and the loss of the 3-layer
organization at level II on at least 1 side of the midbrain.
Two experienced neuroradiologists were invited to identify
“abnormal” SN in SWAN-targeted images acquired in the sample
of patients and controls. Images acquired at 7T and 3T were sep-
arately loaded into a data base and presented in a blinded and
randomized fashion. This process ensured that the readers were
unaware of the clinical diagnosis. Readers were asked to identify
patients with PD according to the “abnormal” appearance of the
SN. Images of each subject were presented twice after an interval
of 7 days to calculate intra- and interrater reliability separately for
7T and 3T imaging. Intra- and interobserver reliability of re-
sponses from each reader were cross-tabulated to enable the
calculation of agreement and the Cohen  statistic.22 The
strength of agreement was considered low for  values of 0.21–
0.40, moderate for  values of 0.41–0.60, good for  values of
0.61–0.80, and excellent for  values of 0.81. Sensitivity,
specificity, positive predictive value, negative predictive value,
and diagnostic accuracy with respect to the clinical diagnosis
were calculated.
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To test the role of radiologic signs in diagnosing PD and to
reduce the bias of previous experiences at high and ultra-high-
field strength magnets, we presented the entire data base of pa-
tients and controls to a third blinded observer with 5 years’ expe-
rience in radiology at our university and whose experience in the
neuroradiology unit includedCT and 1.5TMR imaging studies of
patients with neurodegenerative andmovement disorders but not
with acquisitions on 3T or 7T MR imaging systems. The third
rater was invited to study the SN anatomy and its changes accord-
ing to the most recent literature13,15 regarding the semiology of
the SN in PD. A dataset consisting of 8 midbrain images at 3T (4
HS) and at 7T (4 HS) was used for training purposes. The images
belonging to this training dataset were not included in the rest of
this study. After training, the third rater
evaluated all the 3T and 7T midbrain
images previously presented to the 2 ex-
perienced neuroradiologists in a blinded
and randomized fashion at 2 different
times to calculate sensitivity, specificity,
accuracy, and intraobserver agreement
for 3T and 7T acquisitions.
RESULTS
The diagnostic accuracy, sensitivity,
specificity, positive predictive value, and
negative predictive value for each rater
in each reviewing session are separately
reported in the Table. In the next 2
paragraphs, the diagnostic parameters
are reported as the mean value ob-
tained by the 2 expert raters in the 2
reviewing sessions.
7T MR Imaging of the SN
Sensitivity, specificity, positive predic-
tive value, and negative predictive value
for the diagnosis of PDwere 93%, 100%,
100%, and 93%, respectively.Diagnostic
accuracy was 96%. Intraobserver agree-
ment (  1) and interobserver agree-
ment ( 1) were excellent.
3T MR Imaging of the SN
Sensitivity, specificity, positive predic-
tive value, and negative predictive value
for the diagnosis of PD were 79%, 94%,
94%, and 81%, respectively. Diagnostic
accuracy was 86%. At 3T, intraobserver
agreement was excellent for both raters ( 0.924 for rater 1 and
 0.851 for rater 2) and interobserver agreement was good for
the first reviewing session ( 0.773) and excellent for the second
reviewing session ( 0.851).
Performance of the Third, Less Expert Rater
For the third rater, sensitivity, specificity, positive predictive
value, negative predictive value, and accuracy were 82%, 100%,
100%, 84%, and 89% at 7T and 79%, 100%, 100%, 81%, and 89%
at 3T, respectively. Intraobserver agreementwas good ( 0.773)
at 7T and excellent ( 1) at 3T.
Examples of 3T correct, false-positive, and false-negative read-
ings as classified by rater 2 are shown respectively in Figs 1–3.
FIG 1. SWAN-targeted axial image of the midbrain in a healthy subject evaluated at 3T (right
column) and at 7T (left column). The trilaminar organization of the SN at level II (upper row) and
the nigrosome formation at level I (lower row) are clearly shown with 3T and 7T magnets.
Levels I and II of image acquisition are represented bywhite and gray lines in the scout image.
On 7T images, we overlaid a diagram of the trilaminar structure of the SN derived by
anatomic atlases.41 The diagnostic accuracy is elevated for both high- and ultra-high-field-
strength magnets. cp indicates cerebral peduncle; PBN, parabrachial nucleus; RRF, retrorubral
field; scp, superior cerebellar peduncle; SNcv, substantia nigra pars compacta ventralis; SNcd,
substantia nigra pars compacta dorsalis; SNr, substantia nigra pars reticularis; VTA, ventral
tegmental area; R, red nucleus.
Sensitivity, specificity, PPV and NPV, diagnostic accuracy, and true-positive/true-negative results for each reader in each reading
session
7T 3T
R1 1st R1 2nd R2 1st R2 2nd R3 1st R3 2nd R1 1st R1 2nd R2 1st R2 2nd R3 1st R3 2nd
Sensitivity 93 93 93 93 77 86 79 79 71 86 79 79
Specificity 100 100 100 100 100 100 92 100 92 92 100 100
PPV 100 100 100 100 100 100 92 100 91 92 100 100
NPV 93 93 93 93 81 87 80 81 75 86 81 81
Accuracy 96 96 96 96 85 93 85 89 81 89 89 89
TP/TN 13/13 13/13 13/13 13/13 10/13 12/13 11/12 11/13 10/12 12/12 11/13 11/13
Note:—R indicates reader; TP, true-positive; TN, true-negative; 1st, first reading; 2nd, second reading; NPV, negative predictive value; PPV, positive predictive value.
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DISCUSSION
Our results confirm the capability of 7T MR imaging to reveal,
through visual inspection of SWAN images, the loss of the 3-layer
organization13 and of the lateral bright spot of the SN13,15,16 in
patients with PD, allowing high diagnostic accuracy.
MR imaging at 7T is being tested in different clinical condi-
tions23 to assess its clinical importance for specific situations.24
UHF MR imaging examinations provide encouraging results in
terms of tolerability and acceptance.25,26 At present, around the
world, there are approximately 40 UHFMR imaging systems that
are still confined to the research environment. In this study, we
transferred the semiology adopted at 7T in diagnosing PD to 3T
and verified that the diagnostic gain permitted by UHF could be
extended, at least to some relevant extent, to a clinical scanner that
is more easily accessible for patient care (Fig 1).
With high-resolution target imaging at 3T, we detected a par-
tition of the SN in HS and identified patients with PD as reported
in other recent experiences.17,18 Nevertheless as demonstrated by
the lower intra- and interobserver agreement at 3T, the confi-
dence in revealing the inner structure of the SN was inferior to
that of 7T. The loss of the 3-layer organization of the SNor the loss
of the hyperintense spot in the lateral
component of the intermediate tier of
the SN is less evident at 3T and leaves
some uncertainty in defining the patho-
logic aspect of the SN in PD. As demon-
strated by the higher number of false-
positives and false-negatives at 3T,
identifying the hyperintense central
component of the normal SN (Fig 2) is
more difficult, and the raters tended to
overestimate subtle SN hyperintensities,
which were misinterpreted as normal
(Fig 3). The global effect is the reduction
of the diagnostic accuracy of SWAN se-
quences at 3T with respect to 7T.
Because the MR imaging signal in-
creases quadratically with the field
strength while noise increases only lin-
early, the SNR is theoretically more than
double at 7T with respect to 3T, and this
difference can be exploited to increase
the spatial resolution.27 In our protocol,
the 7T and 3T images have a similar spa-
tial resolution (312 m at 7T versus 364
m at 3T); therefore, this is unlikely to
be the reason for the better performance
of 7T. The superior imaging perfor-
mance of 7T is more likely from the in-
creased T2* contrast and magnetic sus-
ceptibility effects of paramagnetic
substances, which are enhanced at
higher magnetic fields.28-30 The mag-
netic susceptibility effects of iron con-
tained in the SN scale linearly with mag-
netic field strength. At 7T, the larger
susceptibility effect compared with 3T
results in more informative images of
the midbrain with an increased contrast between the 2 hypoin-
tense iron-containing components of the SNand the intermediate
hyperintense part that is preserved in HS (On-line Figure).
From a clinical point of view, a diagnostic error occurs in
10%–25% of patients with parkinsonism; and 20% of patients
with PD coming tomedical attention are not diagnosed as such.31
These diagnoses result in delayed or inappropriate therapy initi-
ation.32 The accuracy of the clinical diagnosis of PD is 90% in a
5-year observation period,33 and the rate of re-diagnosis from PD
to an alternative disease is 5.9%.34 The most frequent wrong dif-
ferential diagnosis is related to atypical parkinsonism35 but also to
nondegenerative movement disorders such as essential tremor,
dystonic tremor, and vascular pseudoparkinsonism.36 More rare
but crucial misdiagnoses are normal pressure hydrocephalus37
and neoplastic lesions.38 The total annual cost of anti-Parkinson
medication for these misdiagnosed patients has been estimated at
£13,400 (US $21,722).34 The potential role of MR imaging would
be to provide an earlier and more accurate diagnosis than the
standard clinical assessment, improving the cost-effectiveness.
The diagnostic accuracy of SWAN imaging at 3T is lower than that
FIG 2. SWAN-targeted axial image of themidbrain in a healthy subject evaluated at 3T (right) and
7T (left). The nigrosome formation appreciable at 7T is interpreted as lost at 3T, generating a
false-positive.
FIG 3. SWAN-targeted axial image of themidbrain in a patient with PD evaluated at 3T (right) and
7T (left). The nigrosome formation seems recognizable in the left SN. On the right SN, the
nigrosome formation is lost at 7T, while at 3T the slight hyperintense component (arrow) has
been erroneously interpreted as a nigrosome, leading to a false-negative finding.
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at 7T but is still high enough to suggest a role in a clinical setting.
Because the sensitivity of the clinical evaluation is high (96%) and
the specificity of the 3T MR imaging is higher than that of the
clinical evaluation in a 5-year period (82%),36 3TMR imaging can
be used in clinical practice as a confirmatory method. In a popu-
lation with a clinical suspicion of PD, the high specificity of 3T
MR imaging allows identifying true-negative subjects, similar to
nuclear medicine with radiotracers for dopamine transporters.39
BecauseMR imaging is a fundamental step in excluding pseudop-
arkinsonism or atypical parkinsonism,40 the use of a 3T clinical
scanner, including the imaging of the SN, seems to be justified in
extrapyramidal disorders.
Unfortunately SN imaging at 3T is less effective than at 7T in
identifying true-positive cases, attenuating its impact. We hy-
pothesize that patients with high clinical suspicion of PD and
negative imaging findings of the SN at 3T might benefit from an
evaluation at 7T. A dedicated study would be necessary to calcu-
late whether the use of the more accurate diagnosis obtained with
7T MR imaging is cost-effective compared with to the use of 3T
MR imaging only.
Regarding the results of the less expert rater unbiased by pre-
vious UHFMR imaging experiences, the high diagnostic accuracy
and intrarater reproducibility at 7T and 3T confirm the robust-
ness of the radiologic semiology consisting of simple and repro-
ducible signs.17
The diagnostic accuracy is inferior at 3T in both expert and less
expert raters, indicating that the confidence in expressing a diag-
nostic judgment depends more on the magnetic field strength
than on the rater’s ability.
Some major limitations should be taken into account. First,
the number of enrolled patients is limited mostly due to the lim-
ited number of patients available for evaluation at 7T. Patients
and controls are not perfectly matched, though they do not differ
significantly. The sequence parameters (TE and flip angle) slightly
differ between the 2 MR imaging scanners. TEs are automatically
determined by the software and cannot be set by the operators,
while the flip angle at 7T is reduced to limit the signal drop related
to the T2 relaxation time shortening at UHF. Finally, although
images were randomly presented, the quality of images obtained
at 7T and 3T is clearly different, and the 2 datasets can be clearly
recognized by the readers, who therefore cannot be considered
blinded with respect to the scanner but only with respect to the
subject’s condition.
CONCLUSIONS
The experience acquired in the research environment by using
7T systems allowed us to develop and refine targeted MR im-
aging acquisitions for 3T scanners, improving the role of imaging
in the diagnosis of PD at a single-subject level in clinical practice.
However if the higher diagnostic accuracy of SWAN at 7T with
respect to 3T could justify the use of the 7T in clinical practice, a
cost-effectiveness study to support this possibility should be
performed.
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